Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
#How Has the Stelara (Ustekinumab) Market Growth Performance Trended Historically, And What Lies Ahead?
The market size of stelara (ustekinumab) has seen significant growth in the recent past. The projected growth will take the market from a worth of $11,177.34 million in 2024 to being valued at $11,850.79 million in 2025, with a compound annual growth rate (CAGR) of 6.0%. The expansion during the historical period is credited to factors such as the increase in healthcare expenditure, development of specialty drug delivery methods, widening of clinical trial initiatives, investments in research and development, and the rising employment of telemedicine for easier treatment access.
What Is the Forecast for the Stelara (Ustekinumab) Market Size Through 2029?
Anticipations for the stelara (ustekinumab) market forecast suggest robust expansion in the coming years, leading to a size of $14,768.48 million by 2029, with a compound annual growth rate (CAGR) of 5.7%. This projected growth throughout the forecast period is credited to the broadening applications for stelara, the escalating occurrence of autoimmune diseases, the drug’s superior effectiveness in refractory instances compared to other options, increasing consciousness among both patients and medical practitioners, and an expanding emphasis on bespoke medicine. The period is expected to witness significant shifts such as the embracement of biologic treatments, the advent of state-of-the-art drug delivery systems, data-centric healthcare systems, collaborations, and licensure contracts among pharmaceutical firms, and progress in biologics production techniques.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19935&type=smp
What are the Key Market Players in Stelara (Ustekinumab) Market and How They’re Evolving?
Major companies operating in the stelara (ustekinumab) market include Johnson & Johnson
What Are the Primary Growth Drivers in the Stelara (Ustekinumab) Market?
An increase in the number of individuals suffering from psoriasis, a chronic autoimmune disorder that fastens the turnover of skin cells, is anticipated to fuel the growth of the Stelara (ustekinumab) market. Several factors account for this increase in psoriasis cases, such as enhanced diagnostic methods, environmental causes, genetic susceptibility, and an elderly population. Stelara (ustekinumab) works by targeting and hindering interleukin-12 and interleukin-23, which assists psoriasis patients by effectively diminishing inflammation and plaque development. This results in better skin clearance and long-term symptom management, thus, enriching their overall lifestyle quality. For example, a report by the US-based National Library of Medicine, released in May 2024, showed that the prevalence of psoriasis grew to 0.221% in 2022, with 6,930 PsA instances recorded in a 3,133,500 strong population. Hence, the surge in the number of psoriasis patients is foreseen to further boost the expansion of the Stelara (ustekinumab) market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=19935&type=smp
What Are the Leading Segments in the Global Stelara (Ustekinumab) Industry?
The stelara (ustekinumab)market covered in this report is segmented –
1) By Indication: Plaque Psoriasis; Psoriatic Arthritis; Crohn’s Disease; Ulcerative Colitis; Other Indications
2) By Route Of Administration: Subcutaneous Injection; Intravenous Infusion
3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
4) By End User: Pediatric; Adult; Geriatric
What Are the Key Market Trends in the Stelara (Ustekinumab) Industry?
The primary development in the Stelara (ustekinumab) market pertains to the creation of novel products, such as Stelara biosimilars, to supply affordable treatment solutions for patients suffering from chronic inflammatory diseases. Biosimilars of Stelara are essentially similar biomedicines formulated to mimic the curative impact of Stelara (Ustekinumab), specifically targeting IL-12 and IL-23 to handle autoimmune diseases like psoriasis and psoriatic arthritis. For example, Accord BioPharma Inc., an American biopharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) in October 2024 for IMULDOSA (ustekinumab-srlf), a biosimilar to Johnson & Johnson’s STELARA (ustekinumab). IMULDOSA is noted for its wide range of indications— it can treat adult patients with moderate to severe plaque psoriasis, active psoriatic arthritis, seriously active Crohn’s disease, and ulcerative colitis. Uniquely, it is also suitable for pediatric patients aged 6 years and above suffering from moderate to severe plaque psoriasis and active psoriatic arthritis, thus proving its utility across various age groups. This extensive scope makes IMULDOSA a very viable prospect for managing a diverse array of immune-mediated inflammatory conditions.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/stelara-ustekinumab-global-market-report-
What Is the Regional Outlook for the Stelara (Ustekinumab) Market?
North America was the largest region in the stelara (ustekinumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the stelara (ustekinumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19935
This Report Delivers Insight On:
1. How big is the stelara (ustekinumab) market, and how is it changing globally?
2. Who are the major companies in the stelara (ustekinumab) market, and how are they performing?
3. What are the key opportunities and risks in the stelara (ustekinumab) market right now?
4. Which products or customer segments are growing the most in the stelara (ustekinumab) market?
5. What factors are helping or slowing down the growth of the stelara (ustekinumab) market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model